greeksoup/ stocks
Stocks / United States / TECH / Q1 FY2026

Bio-Techne Corp. Q1 FY2026 results: revenue $287 million, down 1.0% on the year

Bio-Techne Corp. (TECH) reported revenue of $287 million for Q1 FY2026, the quarter ended 30 September 2025, down 1.0% on the same quarter a year earlier. Net income was $38 million, up 13.6% on the year, and diluted earnings per share $0.24. The figures are the company's own, from the 10-Q it filed with the SEC on 5 November 2025.

Revenue$287 milliondown 1.0%
Net income$38 millionup 13.6%
Diluted EPS$0.24
QuarterQ1 FY2026ended 30 September 2025

The quarter, against the one before and a year earlier

LineQ1 FY2026Q4 FY2025Q1 FY2025Change on the year
Revenue287317289-1.0%
Cost of revenue98.4118106-7.5%
Gross profit188199183+2.8%
Gross margin65.6%62.7%63.2%
Research and development24.226.023.9+1.6%
Selling, general and administrative116197119-2.5%
Operating income47.7-23.940.0+19.2%
Operating margin16.6%-7.5%13.8%
Interest expense2.92.22.2+34.8%
Pre-tax income48.0-22.940.2+19.5%
Income tax9.8-5.26.6+49.2%
Effective tax rate20.4%n/a16.4%
Net income38.2-17.733.6+13.6%
Net margin13.3%-5.6%11.6%
Diluted EPS$0.24-$0.11$0.21+14.3%

$ million except per share. Fourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

LineQ1 FY2026Q4 FY2025Q1 FY2025Change on the year
Operating cash flow27.698.263.9-56.8%
Capital expenditure5.44.99.2-41.5%
Free cash flow22.293.354.7-59.4%
Free cash flow margin7.8%29.4%18.9%
Depreciation and amortisation24.327.128.1-13.5%
Share-based compensation11.74.510.2+14.7%
Buybacks0.0n/an/an/a
Dividends paid12.412.412.7-1.9%
Dividend per share$0.08n/a$0.08+0.0%
Diluted shares, weighted156m160m161m-3.0%
Shares outstanding at period end156m155m159m-2.0%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ1 FY2026Q4 FY2025Q1 FY2025Change on the year
Total assets2,5262,5582,736-7.7%
Cash and equivalents145162188-22.7%
Receivables184207224-17.8%
Inventory203189185+9.8%
Goodwill979981983-0.4%
Long-term debt including finance leases300346300+0.0%
Operating lease liabilities80.784.085.4-5.5%
Shareholders' equity1,9661,9192,139-8.1%

Quarterly results, the last 12 quarters

Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026Q4 FY2026 *
Revenue277273303306289297316317287296311321
Cost of revenue91.796.098.810310610310211898.4105103110
Gross profit185177205203183194215199188191208211
Gross margin67%65%67%66%63%65%68%63%66%65%67%66%
R&D24.022.925.824.023.925.024.626.024.223.123.523.9
SG&A105116112134119121151197116114109113
Operating income55.938.067.045.840.047.438.7-23.947.754.575.574.3
Operating margin20%14%22%15%14%16%12%-8%17%18%24%23%
Interest expense4.94.34.02.52.22.12.02.22.92.22.42.1
Pre-tax income49.633.461.141.740.242.938.3-22.948.050.871.270.7
Tax rate-3%18%20%3%16%19%41%n/a20%25%28%23%
Net income51.027.549.140.633.634.922.6-17.738.238.051.054.6
Net margin18%10%16%13%12%12%7%-6%13%13%16%17%
Diluted EPS$0.31$0.17$0.31$0.26$0.21$0.22$0.14-$0.11$0.24$0.24$0.32$0.36
Operating cash flow59.483.181.075.563.984.341.198.227.682.486.795.4
Capital expenditure13.614.916.418.09.26.810.14.95.45.99.18.5
Free cash flow45.868.364.557.554.777.531.093.322.276.577.686.9
Buybacksn/an/a0.0n/an/an/a100n/a0.00.00.041.7
Dividends paid12.712.612.612.612.712.712.612.412.412.512.512.5
Shares outstanding158m157m158m158m159m158m157m155m156m156m157m156m
Filing10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Source

10-Q for the period ended 30 September 2025, filed 5 November 2025, accession 0001104659-25-107053: the filing on EDGAR. All of Bio-Techne Corp.'s filings: EDGAR company page.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install